NLRP3 and colitis: Finally, phloretin administration reduced DSS-induced colitis by modulating NLRP3, TLR4, and PPARγ pathways, enhancing the expression of ZO-1 and occluding, and reducing serum LPS levels while restoring the balance of Escherichia coli and Lactobacillus in the gut 327.